JMPWA
SMMT icon

JP Morgan Private Wealth Advisors’s Summit Therapeutics SMMT Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50,000
Closed -$80K – 1529
2019
Q4 		$80K Buy
+50,000
New +$80.4K ﹤0.01% 1442

Other funds holding SMMT

LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Inscription Capital Houston, Texas $951M AUM 23.82% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PFBT
Parkside Financial Bank & Trust Saint Louis, Missouri $1.31B AUM 19.14% 1-Year Est. Return

JP Morgan Private Wealth Advisors's SMMT Position: Q1 2020 in Review

JP Morgan Private Wealth Advisors sold out of Summit Therapeutics (SMMT) in Q1 2020, closing a stake of 50,000 shares — an estimated $80K sold.

JP Morgan Private Wealth Advisors first reported a position in SMMT in Q4 2019 and held it in 1 quarter. The position peaked at $80K in Q4 2019. 11 funds tracked by Wall St. Rank hold SMMT as of Q1 2020.

  • JP Morgan Private Wealth Advisors reported no remaining Summit Therapeutics position as of Q1 2020 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 50,000 Summit Therapeutics shares in Q1 2020, an estimated $80K.
  • JP Morgan Private Wealth Advisors first reported a position in Summit Therapeutics in Q4 2019 and held it in 1 quarter.
  • JP Morgan Private Wealth Advisors's Summit Therapeutics position peaked at $80K in Q4 2019.
  • 11 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2020.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q1 2020, filed 13 May 2020.